Asston Pharmaceuticals Limited
BBSE:APL123.94
INR
+5.40
(+4.56%)
ISIN
INE0SJX01015
Return %
Stock
S&P 500
1Y
41.97
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Saili Jayaram More
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Thane India
- IPO Date
- Jul 16, 2025
- Website
- asstonpharmaceuticals.com
- Similar Companies
- Business
- Asston Pharmaceuticals Limited is an India-based pharmaceutical and nutraceutical company engaged in the development, manufacturing, marketing, and distribution of generic pharmaceutical formulations, active dosage forms, and specialized healthcare products. The company operates through two primary business segments, Pharmaceuticals and Nutraceuticals, offering a systematic portfolio of dosage forms that includes generic and branded tablets such as antibiotics, anti-tuberculosis treatments, anthelmintics, antimalarials, and bronchodilators; hard and soft gelatin capsules; oral liquids, syrups, and pediatric suspensions; dry syrups and oral sachets; external topical preparations including medicated ointments, creams, therapeutic gels, and lotions; ophthalmic formulations including eye drops; and parenteral injectables across small volume and large volume parenterals. In addition to commercializing proprietary brands, the company provides comprehensive contract development and manufacturing organization (CDMO) services, loan license manufacturing, and custom formulation solutions for third-party pharmaceutical enterprises. Asston Pharmaceuticals distributes its products across the domestic Indian market and exports finished dosage formulations to international markets across Africa, including Sierra Leone, Ghana, and Liberia, as well as select regions in Asia. Founded in April 2019 and headquartered in Navi Mumbai, Maharashtra, India, the company maintains advanced manufacturing infrastructure in Ambernath, Maharashtra. In recent corporate developments, the company converted from a private entity to a public limited company in August 2024, changing its name from Asston Pharmaceutical Private Limited to Asston Pharmaceuticals Limited; acquired Ferron Lifecare Private Limited to expand its nutraceutical production capabilities; secured regulatory approval from the Food and Drug Administration (FDA) for its Ambernath formulation facility in December 2024, segregating pharmaceutical and FSSAI-compliant nutraceutical production lines; and completed its initial public offering (IPO) on the BSE SME platform in July 2025 under ticker BSE: 544445 (APL) to finance working capital requirements and fund facility capacity expansion.